INSOMNIA DISORDER

SCF-RDOS INDICATION REGISTRY ENTRY

Classification

DEFINITION

INSOMNIA DISORDER is a sleep-wake disorder characterized by persistent difficulty initiating sleep, maintaining sleep, returning to sleep following awakenings, or obtaining restorative sleep despite adequate opportunity and circumstances for sleep.

The disorder results in clinically significant daytime impairment including fatigue, cognitive dysfunction, emotional dysregulation, reduced productivity, impaired attention, decreased quality of life, and elevated risk for numerous psychiatric, neurological, cardiovascular, metabolic, and immune-related conditions.

Within the SCF-RDOS framework, Insomnia Disorder is conceptualized as a hyperarousal and sleep-regulation disorder involving dysfunction across arousal-control systems, circadian timing networks, sleep-homeostasis mechanisms, neuroendocrine regulation pathways, emotional-regulation circuits, and neuroenergetic recovery architecture.

ETIOPATHOGENIC CORE

Primary Pathogenic Theme

Persistent physiological, cognitive, emotional, or circadian hyperarousal interferes with normal sleep initiation, maintenance, and restoration, leading to chronic sleep disruption and downstream multisystem dysfunction.

Core Pathogenic Drivers

SCF FAULT ARCHITECTURE

Tier 1 — Sleep Vulnerability Layer

Predisposing Factors

Potential contributors include:

• Family history of insomnia
• Anxiety disorders
• Depression
• Chronic stress
• Trauma exposure
• Shift work
• Circadian rhythm disorders
• Chronic medical conditions
• Excessive stimulant use
• Aging-related sleep changes

Physiological Vulnerabilities

Common contributors include:

• Hyperresponsive stress systems
• Circadian instability
• Increased cortical arousal
• Emotional reactivity
• Neuroendocrine imbalance
• Sleep-homeostasis disruption

Tier 2 — Hyperarousal and Sleep Dysregulation

Sleep-Initiation Dysfunction

Individuals may experience:

• Difficulty falling asleep
• Excessive bedtime alertness
• Racing thoughts
• Sleep-performance anxiety
• Prolonged sleep latency

Sleep-Maintenance Dysfunction

Manifestations may include:

Tier 3 — Insomnia Disorder Consolidation

Sleep Symptoms

Manifestations include:

• Difficulty initiating sleep
• Difficulty maintaining sleep
• Early-morning awakening
• Non-restorative sleep
• Reduced sleep efficiency
• Fragmented sleep architecture
• Sleep dissatisfaction
• Persistent sleep concerns

Cognitive Symptoms

Manifestations include:

• Brain fog
• Reduced concentration
• Memory impairment
• Slowed information processing
• Executive dysfunction
• Cognitive fatigue

Emotional Symptoms

Manifestations include:

• Anxiety
• Irritability
• Mood instability
• Emotional exhaustion
• Frustration
• Reduced stress tolerance

Physiological Symptoms

Manifestations include:

• Fatigue
• Reduced physical endurance
• Daytime sleepiness
• Autonomic hyperarousal
• Headaches
• Somatic tension

Tier 4 — Functional and Multisystem Decompensation

Potential outcomes include:

• Occupational impairment
• Academic dysfunction
• Anxiety disorders
• Major depressive episodes
• Burnout syndromes
• Cognitive decline
• Cardiovascular risk elevation
• Metabolic dysfunction
• Immune dysregulation
• Reduced quality of life

MOLECULAR MULTI-OMICS PATHOGENESIS MAP

Genomics

Potential susceptibility systems:

• Circadian-clock genes
• Sleep-regulation pathways
• Stress-response regulators
• Emotional-regulation genes
• Neuroplasticity pathways

Epigenomics

Potential alterations:

• Stress-related methylation signatures
• Circadian regulatory remodeling
• Hyperarousal-associated adaptations
• Neuroendocrine pathway modifications

Transcriptomics

Potential dysregulated pathways:

• Sleep-homeostasis networks
• Circadian timing systems
• Stress-response pathways
• Arousal-maintenance mechanisms

Proteomics

Potential abnormalities:

• Circadian proteins
• Neuroplasticity mediators
• Stress-response proteins
• Neuroendocrine regulators

Metabolomics

Potential disturbances:

• Cortisol dysregulation
• Melatonin rhythm disruption
• Catecholamine imbalance
• Neuroenergetic inefficiency
• Glucose-metabolism alterations

Interactomics

Potential network dysfunction:

• Hyperarousal–insomnia reinforcement loops
• Stress–sleep disruption cascades
• Anxiety–wakefulness maintenance pathways
• Circadian–cognitive impairment networks

Connectomics

Frequently implicated neural circuits:

Adapted from SCF multi-omic pathophysiology reconstruction principles.

PATHOGENESIS FLOW (SCF LOGIC)

Sleep Vulnerability

↓

Stress or Circadian Disruption

↓

Hyperarousal Activation

↓

Difficulty Initiating or Maintaining Sleep

↓

Sleep Fragmentation

↓

Reduced Sleep Restoration

↓

Daytime Cognitive and Emotional Dysfunction

↓

Sleep-Related Anxiety

↓

Insomnia Maintenance Cycle

↓

Insomnia Disorder

CLINICAL PRESENTATION

Sleep Symptoms

• Difficulty falling asleep
• Frequent awakenings
• Early-morning awakening
• Non-restorative sleep
• Poor sleep quality
• Reduced sleep duration

Cognitive Symptoms

• Brain fog
• Memory impairment
• Reduced concentration
• Executive dysfunction
• Cognitive fatigue
• Mental slowing

Emotional Symptoms

• Anxiety
• Irritability
• Mood instability
• Emotional exhaustion
• Frustration
• Reduced resilience

Physiological Symptoms

• Fatigue
• Somatic tension
• Headaches
• Reduced physical performance
• Daytime sleepiness
• Autonomic activation

Functional Symptoms

• Occupational impairment
• Academic decline
• Reduced productivity
• Social dysfunction
• Relationship strain
• Quality-of-life deterioration

PATHOGENS → SYMPTOMATOLOGY → SCF FAULT TIER MAPPING

ASSOCIATED CONDITIONS

Insomnia Disorder commonly overlaps with:

• Generalized Anxiety Disorder
• Major Depressive Disorder
• PTSD
• Complex PTSD
• Circadian Rhythm Sleep Disorders
• Cognitive Fatigue Syndrome
• Executive Burnout
• Chronic Psychological Exhaustion
• Chronic Pain Disorders
• Substance Use Disorders
• Obstructive Sleep Apnea

DIAGNOSTIC CONSIDERATIONS

Core Diagnostic Features

Individuals commonly demonstrate:

• Persistent difficulty initiating or maintaining sleep
• Adequate opportunity for sleep
• Significant daytime impairment
• Symptoms occurring repeatedly over time
• Sleep dissatisfaction
• Functional consequences attributable to sleep disturbance

Differential Considerations

SCF THERAPEUTIC MECHANISMS

SCF-PCR PREVENTATIVE

Objectives

• Preserve healthy sleep architecture
• Stabilize circadian rhythms
• Reduce hyperarousal
• Improve sleep resilience
• Prevent chronic insomnia consolidation

SCF-PCR CURATIVE

Therapeutic Targets

Sleep Regulation Layer

• Sleep initiation optimization
• Sleep-maintenance restoration
• Sleep-quality enhancement

Circadian Layer

• Circadian synchronization
• Biological-timing stabilization
• Light–dark rhythm optimization

Hyperarousal Layer

• Stress-system reduction
• Cognitive-rumination interruption
• Physiological relaxation enhancement

Cognitive Layer

• Sleep-related anxiety reduction
• Cognitive restructuring
• Behavioral conditioning reversal

Neuroenergetic Layer

• Recovery optimization
• Fatigue reduction
• Cognitive restoration

SCF-PCR RESTORATIVE

Functional Restoration Goals

• Consistent restorative sleep
• Improved daytime functioning
• Emotional stability
• Cognitive recovery
• Occupational resilience
• Long-term sleep health

CURRENT EVIDENCE-BASED TREATMENT APPROACHES

Behavioral and Psychological Interventions

First-Line Treatment

• Cognitive Behavioral Therapy for Insomnia (CBT-I)
• Sleep Restriction Therapy
• Stimulus Control Therapy
• Relaxation Training
• Mindfulness-Based Sleep Interventions

Therapeutic Objectives

• Reduce hyperarousal
• Improve sleep efficiency
• Restore healthy sleep associations
• Improve long-term sleep stability

Lifestyle and Environmental Interventions

• Consistent sleep schedule
• Circadian-light management
• Reduction of stimulant exposure
• Sleep-environment optimization
• Stress-management programs
• Physical activity optimization

Pharmacologic Considerations

Pharmacologic interventions may be considered when clinically indicated and should be individualized according to:

• Severity of insomnia
• Duration of symptoms
• Comorbid psychiatric conditions
• Medical status
• Functional impairment

Behavioral interventions remain the preferred long-term management strategy due to sustained efficacy and reduced risk of dependence.

PROGNOSIS

Prognosis is influenced by:

• Duration of insomnia
• Stress burden
• Circadian stability
• Psychiatric comorbidity
• Treatment adherence
• Sleep-hygiene practices
• Medical comorbidities
• Lifestyle factors

Many individuals achieve substantial improvement through evidence-based behavioral therapies, circadian stabilization, stress reduction, and management of contributing medical or psychiatric conditions.

SCF THERAPEUTIC MECHANISMS (SCF-PCR BRAID)

Preventative

• Sleep-health promotion
• Circadian optimization
• Stress-management enhancement
• Early sleep-disruption intervention

Curative

• Hyperarousal reduction
• Sleep restoration
• Behavioral reconditioning
• Cognitive restructuring

Restorative

• Cognitive recovery
• Emotional resilience
• Functional restoration
• Long-term sleep stability

PROJECT RHENOVA — INTEGRATION PATHWAYS

Research Axis 1

Multi-omic characterization of insomnia and hyperarousal phenotypes.

Research Axis 2

Sleep-regulation and circadian biomarker discovery programs.

Research Axis 3

Sleep-network and arousal-system connectomics mapping.

Research Axis 4

Stress–circadian–sleep interaction pathway modeling.

Research Axis 5

Precision therapeutic frameworks for insomnia-spectrum disorders.

NEXT STRATEGIC RESEARCH PATHWAYS

1. Insomnia biomarker discovery programs.
2. Hyperarousal neurobiology investigations.
3. Circadian-regulation and sleep-network connectomics studies.
4. Neuroendocrine and stress-system pathway characterization.
5. Neuroplasticity mechanisms underlying insomnia persistence and recovery.
6. Digital phenotyping of sleep-disruption trajectories.
7. AI-assisted insomnia-risk prediction systems.
8. Precision treatment-response biomarker development.
9. Sleep–cognition–emotion interaction research.
10. Functional outcome endpoint development for Insomnia Disorder prevention, treatment, rehabilitation, and long-term sleep restoration.

INDEX — SCF-RDOS-IND-001

Registry Code: SCF-RDOS-IND-001

Indication: Insomnia Disorder

Domain: Sleep-Wake Disorders

Framework Version: SCF-RDOS Sleep and Circadian Disorders Registry v1.0

Classification Tier: Insomnia Spectrum Disorder

Research Status: Translational Characterization Candidate

Document Type: SCF Pathophysiology and Therapeutic Development Blueprint

Registry Position: IND-001-2026